AKT1 and Alzheimer disease: As expected, our analysis showed that GRg1 and GRb1 exert multi-level anti-AD effects; for example, the MAPK signaling pathway, Notch signaling pathway, PI3K-Akt signaling pathway, and GO terms (e.g., GO: 0000188, GO: 0007420, and GO: 0031175) were affected.